Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Nature Biotechnology | Generative Chemistry Enables Insilico to Develop Gut-Restricted PHD Inhibitors Promising for Intestinal Mucosal Barrier Repair and Immunomodulation 2024-12-11 22:25
Waterdrop Inc. Announces Third Quarter 2024 Unaudited Financial Results 2024-12-11 18:20
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer 2024-12-11 18:05
Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion 2024-12-11 14:44
Call for Application for 2025 Tsinghua Amgen Scholars Program 2024-12-11 14:33
Syrebo Unveils Innovative Rehab Robots at MEDICA 2024: A Spectacular Showcase! 2024-12-11 14:00
2024 PHBS-CJBS Global Pitch Competition Grand Final Held 2024-12-11 12:29
AXA and HKBN Deepen Collaboration with Launch of "HKBN SmartTraveller Plus" 2024-12-11 11:52
Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment 2024-12-11 11:04
Community Med Care's " Uplift with Love - Angel Mission" 6th Anniversary 2024-12-11 09:00
Partnership Established to Advance WHO's Road Map for Neglected Tropical Diseases 2021-2030 2024-12-11 09:00
【2024 ASH】TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies 2024-12-10 23:00
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months 2024-12-10 22:31
Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety 2024-12-10 22:20
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib 2024-12-10 21:34
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax 2024-12-10 21:30
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report 2024-12-10 21:27
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib 2024-12-10 21:26
Terumo Health Outcomes and Medis Medical Imaging Announce Strategic Partnership to Enhance Cardiovascular Care 2024-12-10 21:00
Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL 2024-12-10 20:48
1 5 6 7 8 9 1612